The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus.

SLE, a chronic, multisystem autoimmune disorder with a broad range of symptoms, involves defective B cell selection and elimination of self-reactive B cells. B lymphocyte stimulator (BLyS), a soluble ligand of the TNF cytokine family, is a prominent factor in B cell differentiation, homeostasis, and selection. BLyS levels affect survival signals and selective apoptosis of autoantibody-producing B cells. High levels of BLyS may relax B cell selection and contribute to autoantibody production, exacerbating the SLE disease state. This review discusses the mechanism of BLyS action on B cells, its role in SLE, and specific targeting of BLyS in the treatment of SLE.

[1]  Ulrich Siebenlist,et al.  Constitutive Nuclear Factor κB Activity Is Required for Survival of Activated B Cell–like Diffuse Large B Cell Lymphoma Cells , 2001, The Journal of experimental medicine.

[2]  I. Sanz,et al.  B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. , 2004, Arthritis and rheumatism.

[3]  S. Shinton,et al.  Resolution of Three Nonproliferative Immature Splenic B Cell Subsets Reveals Multiple Selection Points During Peripheral B Cell Maturation1 , 2001, The Journal of Immunology.

[4]  T. Habermann,et al.  Expression of BLyS and its receptors in B-cell non-Hodgkin lymphoma: correlation with disease activity and patient outcome. , 2004, Blood.

[5]  A. Basten,et al.  Reduced life span of anergic self-reactive B cells in a double- transgenic model , 1994, The Journal of experimental medicine.

[6]  C. Ni,et al.  Key Molecular Contacts Promote Recognition of the BAFF Receptor by TNF Receptor-Associated Factor 3: Implications for Intracellular Signaling Regulation1 , 2004, The Journal of Immunology.

[7]  J. V. van Deursen,et al.  Regulation of the T-independent humoral response by TACI. , 2001, Immunity.

[8]  T. Phan,et al.  Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. , 2004, Immunity.

[9]  S. Nish,et al.  The regulation and activation potential of autoreactive B cells , 2003, Immunologic research.

[10]  J. Tschopp,et al.  Baff Binds to the Tumor Necrosis Factor Receptor–Like Molecule B Cell Maturation Antigen and Is Important for Maintaining the Peripheral B Cell Population , 2000, The Journal of experimental medicine.

[11]  M. Nussenzweig,et al.  Predominant Autoantibody Production by Early Human B Cell Precursors , 2003, Science.

[12]  P. Schneider,et al.  BAFF, APRIL and their receptors: structure, function and signaling. , 2006, Seminars in immunology.

[13]  B. Diamond,et al.  Similarities and differences between selective and nonselective BAFF blockade in murine SLE. , 2006, The Journal of clinical investigation.

[14]  M. Petri.  Detection of coronary artery disease and the role of traditional risk factors in the Hopkins Lupus Cohort , 2000, Lupus.

[15]  M. Scott,et al.  An Essential Role for BAFF in the Normal Development of B Cells Through a BCMA-Independent Pathway , 2001, Science.

[16]  T. McGaha,et al.  APRIL is critical for plasmablast survival in the bone marrow and poorly expressed by early-life bone marrow stromal cells. , 2008, Blood.

[17]  P. Moore,et al.  Synthesis and release of B-lymphocyte stimulator from myeloid cells. , 2001, Blood.

[18]  T. Cachero,et al.  Crystal structure of extracellular human BAFF, a TNF family member that stimulates B lymphocytes. , 2002, Journal of molecular biology.

[19]  M. Dalakas,et al.  B cells as therapeutic targets in autoimmune neurological disorders , 2008, Nature Clinical Practice Neurology.

[20]  G. Burmester,et al.  New approaches of B-cell-directed therapy: beyond rituximab , 2008, Current opinion in rheumatology.

[21]  N. Kamatani,et al.  Excessive Production of IFN-γ in Patients with Systemic Lupus Erythematosus and Its Contribution to Induction of B Lymphocyte Stimulator/B Cell-Activating Factor/TNF Ligand Superfamily-13B1 , 2008, The Journal of Immunology.

[22]  G. Bishop,et al.  Mechanisms of TNF receptor‐associated factor (TRAF) regulation in B lymphocytes , 2002, Journal of leukocyte biology.

[23]  C. Grimaldi,et al.  Mechanism of Action of Transmembrane Activator and Calcium Modulator Ligand Interactor-Ig in Murine Systemic Lupus Erythematosus1 , 2004, The Journal of Immunology.

[24]  K. Costenbader,et al.  What can epidemiology tell us about systemic lupus erythematosus? , 2007, International journal of clinical practice.

[25]  C. Mok.  Therapeutic options for resistant lupus nephritis. , 2006, Seminars in arthritis and rheumatism.

[26]  V. Pascual,et al.  Dendritic cells control B cell growth and differentiation. , 2005, Current directions in autoimmunity.

[27]  X. Mariette,et al.  Expression of BAFF (BLyS) in T cells infiltrating labial salivary glands from patients with Sjögren's syndrome , 2004, The Journal of pathology.

[28]  M. Nussenzweig,et al.  A checkpoint for autoreactivity in human IgM+ memory B cell development , 2006, The Journal of experimental medicine.

[29]  J. Sibilia.  Novel concepts and treatments for autoimmune disease: ten focal points. , 2004, Joint, bone, spine : revue du rhumatisme.

[30]  M. Cancro,et al.  Space, Selection, and Surveillance: Setting Boundaries with BLyS1 , 2006, The Journal of Immunology.

[31]  C. Gordon,et al.  Assessment of patients with systemic lupus erythematosus and the use of lupus disease activity indices. , 2005, Best practice & research. Clinical rheumatology.

[32]  G. Hughes,et al.  Systemic lupus erythematosus , 2001, The Lancet.

[33]  N. Rose.  Autoimmune diseases. , 1981, Scientific American.

[34]  D. Landau,et al.  The B lymphocyte stimulator receptor–ligand system in hepatitis C virus-induced B cell clonal disorders , 2008, Annals of the rheumatic diseases.

[35]  Meit A. Bjorndahl,et al.  Articles on similar topics can be found in the following Blood collections , 2006 .

[36]  M. Peterson,et al.  Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. , 2005, Arthritis and rheumatism.

[37]  C. Gregory,et al.  Enhanced Apoptotic Cell Clearance Capacity and B Cell Survival Factor Production by IL-10-Activated Macrophages: Implications for Burkitt’s Lymphoma1 , 2005, The Journal of Immunology.

[38]  D. Gladman,et al.  Association of a gene expression profile from whole blood with disease activity in systemic lupus erythaematosus , 2007, Annals of the rheumatic diseases.

[39]  J. Tschopp,et al.  BAFF-R, a Newly Identified TNF Receptor That Specifically Interacts with BAFF , 2001, Science.

[40]  J. Monroe,et al.  Tonic B cell antigen receptor signals supply an NF-κB substrate for prosurvival BLyS signaling , 2008, Nature Immunology.

[41]  B. Nardelli,et al.  G-CSF–stimulated Neutrophils Are a Prominent Source of Functional BLyS , 2003, The Journal of experimental medicine.

[42]  F. Mackay,et al.  B cells flying solo , 2008, Immunology and cell biology.

[43]  M. Petri.  Monitoring systemic lupus erythematosus in standard clinical care. , 2007, Best practice & research. Clinical rheumatology.

[44]  M. Cancro,et al.  Bcmd decreases the life span of B-2 but not B-1 cells in A/WySnJ mice. , 1998, Journal of immunology.

[45]  W. Anderson,et al.  Residues that mediate DNA binding of autoimmune antibodies. , 1993, Journal of immunology.

[46]  J. Tschopp,et al.  Mice Transgenic for Baff Develop Lymphocytic Disorders along with Autoimmune Manifestations , 1999, The Journal of experimental medicine.

[47]  J. Cyster,et al.  Competition for follicular niches excludes self-reactive cells from the recirculating B-cell repertoire , 1994, Nature.

[48]  V. Dixit,et al.  Identification of a novel receptor for B lymphocyte stimulator that is mutated in a mouse strain with severe B cell deficiency , 2001, Current Biology.

[49]  J. Green,et al.  The association of HLA‐linked genes with systemic lupus erythematosus , 1986, Annals of human genetics.

[50]  M. Hochberg,et al.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. , 1997, Arthritis and rheumatism.

[51]  R. Voll,et al.  SLE--a disease of clearance deficiency? , 2005, Rheumatology.

[52]  D. Lawrence,et al.  APRIL-Deficient Mice Have Normal Immune System Development , 2004, Molecular and Cellular Biology.

[53]  J. Satia,et al.  Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden , 2006, Lupus.

[54]  C. Janeway,et al.  A B-cell receptor-specific selection step governs immature to mature B cell differentiation. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[55]  H. Shu,et al.  B cell maturation protein is a receptor for the tumor necrosis factor family member TALL-1. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[56]  R. Geha,et al.  TACI is mutant in common variable immunodeficiency and IgA deficiency , 2005, Nature Genetics.

[57]  M. Liang,et al.  The epidemiology of systemic lupus erythematosus in populations of African ancestry: a critical review of the "prevalence gradient hypothesis". , 1998, Arthritis and rheumatism.

[58]  B. Seed,et al.  B Cell Maturation Antigen, the Receptor for a Proliferation-Inducing Ligand and B Cell-Activating Factor of the TNF Family, Induces Antigen Presentation in B Cells1 , 2005, The Journal of Immunology.

[59]  M. Crow,et al.  Interferon-α in systemic lupus erythematosus , 2004 .

[60]  Amy S Orr,et al.  BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. , 1999, Science.

[61]  M. Pelletier,et al.  Expression and occupancy of BAFF-R on B cells in systemic lupus erythematosus. , 2005, Arthritis and rheumatism.

[62]  Yun Hee Cho,et al.  BLyS inhibition eliminates primary B cells but leaves natural and acquired humoral immunity intact , 2008, Proceedings of the National Academy of Sciences.

[63]  H. Shu,et al.  Crystal Structure of sTALL-1 Reveals a Virus-like Assembly of TNF Family Ligands , 2002, Cell.

[64]  A. Basten,et al.  Whither the anergic B-cell? , 1994, Autoimmunity.

[65]  V. Roschke,et al.  Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. , 2003, Arthritis and rheumatism.

[66]  D. Lacey,et al.  Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[67]  R. Siegel,et al.  Cardiovascular manifestations of systemic lupus erythematosus. , 1985, American heart journal.

[68]  M. Cancro,et al.  The role of BLyS/BLyS receptors in anti-chromatin B cell regulation. , 2007, International immunology.

[69]  C. Ware,et al.  ΔBAFF, an Alternate Splice Isoform That Regulates Receptor Binding and Biopresentation of the B Cell Survival Cytokine, BAFF* , 2003, Journal of Biological Chemistry.

[70]  R. Geha,et al.  Impaired IgA class switching in APRIL-deficient mice. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[71]  V. Roschke,et al.  Local production of B lymphocyte stimulator protein and APRIL in arthritic joints of patients with inflammatory arthritis. , 2003, Arthritis and rheumatism.

[72]  B. Nardelli,et al.  DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL , 2002, Nature Immunology.

[73]  K. Rajewsky,et al.  Canonical NF-kappaB activity, dispensable for B cell development, replaces BAFF-receptor signals and promotes B cell proliferation upon activation. , 2006, Immunity.

[74]  D. Hilbert,et al.  Competition for BLyS-mediated signaling through Bcmd/BR3 regulates peripheral B lymphocyte numbers , 2001, Current Biology.

[75]  D. Danilenko,et al.  Anti-BR3 antibodies: a new class of B-cell immunotherapy combining cellular depletion and survival blockade. , 2007, Blood.

[76]  R. Geha,et al.  Cutting Edge: The Dependence of Plasma Cells and Independence of Memory B Cells on BAFF and APRIL1 , 2008, The Journal of Immunology.

[77]  M. Cancro,et al.  Peripheral B cell maturation. II. Heat-stable antigen(hi) splenic B cells are an immature developmental intermediate in the production of long-lived marrow-derived B cells. , 1993, Journal of immunology.

[78]  D. Isenberg,et al.  An open study of B lymphocyte depletion in systemic lupus erythematosus. , 2002, Arthritis and rheumatism.

[79]  D. Nemazee,et al.  Clonal deletion of autoreactive B lymphocytes in bone marrow chimeras. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[80]  B. Aggarwal,et al.  Identification and Characterization of a Novel Cytokine, THANK, aTNF Homologue That ActivatesApoptosis, Nuclear Factor-κB, and c-Jun NH2-Terminal Kinase* , 1999, The Journal of Biological Chemistry.

[81]  C. Hayes,et al.  Enforced bcl-xL Gene Expression Restored Splenic B Lymphocyte Development in BAFF-R Mutant Mice1 , 2003, The Journal of Immunology.

[82]  J. Tschopp,et al.  BAFF, a Novel Ligand of the Tumor Necrosis Factor Family, Stimulates B Cell Growth , 1999, The Journal of experimental medicine.

[83]  R. Brink,et al.  TRAF2 differentially regulates the canonical and noncanonical pathways of NF-kappaB activation in mature B cells. , 2004, Immunity.

[84]  E. Clark,et al.  BAFF regulates B cell survival by downregulating the BH3-only family member Bim via the ERK pathway , 2005, The Journal of experimental medicine.

[85]  R Hal Scofield,et al.  Development of autoantibodies before the clinical onset of systemic lupus erythematosus. , 2003, The New England journal of medicine.

[86]  Don Foster,et al.  TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease , 2000, Nature.

[87]  P. Sideras,et al.  B Cell Development in the Spleen Takes Place in Discrete Steps and Is Determined by the Quality of B Cell Receptor–Derived Signals , 1999, The Journal of experimental medicine.

[88]  G. Burmester,et al.  Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus , 2006, Arthritis research & therapy.

[89]  R. Hardy,et al.  B cell development pathways. , 2001, Annual review of immunology.

[90]  J. Merrill,et al.  Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus , 2008, Arthritis research & therapy.

[91]  M. Scott,et al.  Cutting Edge: BAFF Regulates CD21/35 and CD23 Expression Independent of Its B Cell Survival Function , 2004, The Journal of Immunology.

[92]  S. Camper,et al.  Receptor editing: an approach by autoreactive B cells to escape tolerance , 1993, The Journal of experimental medicine.

[93]  G. Bishop.  The multifaceted roles of TRAFs in the regulation of B-cell function , 2004, Nature Reviews Immunology.

[94]  G. Nossal,et al.  Evidence for the clonal abortion theory of B-lymphocyte tolerance , 1975, The Journal of experimental medicine.

[95]  D. Hilbert,et al.  Cutting Edge: BLyS Enables Survival of Transitional and Mature B Cells Through Distinct Mediators1 , 2002, The Journal of Immunology.

[96]  S. Smith‐Gill,et al.  Altered immunoglobulin expression and functional silencing of self-reactive B lymphocytes in transgenic mice , 1988, Nature.

[97]  Kenneth G. C. Smith,et al.  Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment. , 2006, Arthritis and rheumatism.

[98]  M. Genovese,et al.  Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I/II randomized, blinded, placebo-controlled, dose-ranging study. , 2008, Arthritis and rheumatism.

[99]  D. Isenberg,et al.  B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. , 2005, Rheumatology.

[100]  D. Isenberg,et al.  B cell depletion therapy in systemic lupus erythaematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response , 2007 .

[101]  D. Greaves,et al.  ΔBAFF, a Splice Isoform of BAFF, Opposes Full-Length BAFF Activity In Vivo in Transgenic Mouse Models1 , 2005, The Journal of Immunology.

[102]  M. Tourigny,et al.  Attenuation of Apoptosis Underlies B Lymphocyte Stimulator Enhancement of Humoral Immune Response , 2000, The Journal of experimental medicine.

[103]  M. McClain,et al.  The prevalence, onset, and clinical significance of antiphospholipid antibodies prior to diagnosis of systemic lupus erythematosus. , 2004, Arthritis and rheumatism.

[104]  Beatrice Gralton,et al.  Washington DC - USA , 2008 .

[105]  K. Kalunian,et al.  Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial. , 2007, Arthritis and rheumatism.